TY - JOUR T1 - Impact of a Clinical Decision Support Intervention on Albumin Utilization and Appropriateness of Use in an Academic Healthcare System JF - medRxiv DO - 10.1101/2021.04.05.21254943 SP - 2021.04.05.21254943 AU - Prashant R. Mudireddy AU - Nikhil K. Mull AU - Kendal Williams AU - Jennifer Lukaszewicz Bushen AU - Nishaminy Kasbekar AU - Karen Krok AU - Asaf Hanish AU - Benjamin French AU - Craig A. Umscheid Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/07/2021.04.05.21254943.abstract N2 - Background Albumin is expensive compared to crystalloid intravenous fluids and may be used for inappropriate indications, resulting in low value care.Aim/Purpose To study the impact of a computerized clinical decision support (CDS) intervention on albumin utilization and appropriateness of use in an academic healthcare system.Methods A systematic review examining appropriate indications for albumin use in the healthcare setting was used by an interprofessional group of stakeholders locally to develop a CDS intervention to improve the appropriateness of albumin utilization. The order set was implemented across our healthcare system on 4/12/2011, included a list of appropriate indications, and automatically provided albumin concentration, dose and frequency based on the indication selected and patient weight and creatinine. We measured units of albumin ordered across the healthcare system and individually at each of three hospitals in the healthcare system 12 months before and after intervention implementation. An interrupted time series analysis using monthly data examined changes in the level and slope of albumin use during pre-versus post-implementation periods. We also reviewed charts of all adult inpatients receiving albumin in the 3 months prior to and following implementation of the order set at two of the three hospitals within the healthcare system, to determine if “appropriateness” of use had changed, as defined by our consensus criteria. We selected the two hospitals with the most frequent use of albumin in the pre-period. We used chi square tests to compare changes in the proportion of appropriate instances and grams of albumin used. We considered a p-value <0.05 as statistically significant.Results The number of patient encounters analyzed in the 12 months before and after the albumin CDS intervention was 79,108, and 78,240, respectively. There was a statistically significant decrease in mean units of albumin ordered immediately post-intervention across the healthcare system (−4.98 units per 1000 patient days, confidence interval −9.64 to −0.33, p=0.04). At Hospital 1, there were no statistically significant changes in albumin ordering over time. At Hospital 2, albumin ordering significantly increased up to the intervention, but decreased significantly immediately following the intervention and continued to decrease significantly over time following the intervention; the pre and post implementation slopes were significantly different. At Hospital 3, albumin ordering was statistically unchanged up to the intervention, decreased significantly immediately following the intervention, and significantly increased over time following the intervention, but the pre and post slopes were not statistically different. At Hospitals 1 and 3, there was a statistically significant improvement in “appropriateness” of albumin use in the three months following implementation.Conclusions Implementation of a CDS intervention was associated with an increase in the amount of albumin administered appropriately at two hospitals within an academic healthcare system and an overall decrease in albumin utilization across the healthcare system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Umscheid's contribution to this project was supported in part by the National Center for Research Resources, Grant UL1RR024134, which is now at the National Center for Advancing Translational Sciences, Grant UL1TR000003. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received expedited approval and a Health Insurance Portability and Accountability Act (HIPAA) waiver from the University of Pennsylvania Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAggregate data is presented in the manuscript. The IRB approval does not authorize sharing of study data with those outside of the research team. ER -